Early Experience With Remdesivir To Treat Severe COVID-19 PublishedEnlarge this image toggle caption Ulrich Perrey/POOL/AFP via Getty Images Ulrich Perrey/POOL/AFP via Getty ImagesGilead Sciences is reporting some preliminary results from the use of its antiviral drug remdesivir in treating patients with COVID-19.
The study, published Friday by the New England Journal of Medicine, evaluated the response of 53 patients given remdesivir on a compassionate use basis.
The patients received the drug between Jan. 25 and March 7 of this year.
More than half the patients in the study experienced side effect from the drug, ranging from a rash and diarrhea to acute kidney injury.
As the authors note, several factors make it hard to interpret the results on the study.